NOD1 polymorphisms associated with increased activity of the receptor have been linked with augmented risks to develop atopic dermatitis, asthma and inflammatory bowel disease [63]–[67], and TLR2 has been involved in the development of allergic contact dermatitis as well as arthritis in different experimental models [68]–[70]. Here, TLR2 is linked to atopic eczema.